According to the latest ESHIR guideline (62), SPRMs such as medroxyprogesterone acetate and levonorgestrel are highly recommended to reduce endometriosis-associated pain, and norethindrone acetate (alongside GnRH) highly recommended to prevent bone loss and hypoestrogenic symptom, but no longer recommended for danazol. This evidence concerns the gene GNRH1 and endometriosis.